DividendAugust 5, 2026

Dividend Win Wednesday: Energy Insiders Buy at 14% Off While Semiconductors Sit 91% Down

Top 5 Pixie Picks

This Week's Setup

ConocoPhillips and Newmont hold the top two dividend ranks while KLA Corporation trades at a 90.7% drawdown with a 15.0% free cash flow yield, the deepest discount on the screen.

Insider buying persists across energy and pharma names, with EOG Resources executives selling modest amounts while Biogen directors add shares.

Fear & Greed sits at 63 while the S&P 500 CAPE holds at 38.9, consistent with the elevated long-cycle valuations that have defined the past 18 months.

Quick Scan

#	Ticker	One-line thesis
1	COP	Energy at 14% off with insider adds and 5.1% FCF yield
2	NEM	Gold miner at 28% drawdown with 7.0% FCF yield
3	NVS	Swiss pharma with 3.1% yield and 10% drawdown
4	EOG	Energy producer near highs with 4.5% FCF yield
5	BIIB	Biotech with insider buying and 6.6% FCF yield
6	KLAC	Semiconductor equipment at 91% off with 15.0% FCF
7	CI	Health insurer at 19% drawdown with 11.6% FCF yield
8	GILD	HIV and oncology franchise with 5.8% FCF yield

The 8 Names

1. ConocoPhillips (COP)

Dividend yield: 2.9% | Payout ratio: 51.3% | 52w drawdown: 13.7%

The setup here is 5.1% FCF yield at a 13.7% drawdown with a 2.9% dividend yield and 51% payout ratio, leaving room for buybacks or distribution growth. Revenue climbed 7.7% year-over-year while ROIC sits at 13.5%, above the sector median for integrated producers.

Silvina Vatnick filed three Form 4 transactions between July 10 and July 27, adding shares while the stock traded in the $115–$120 range. Net debt sits at 0.73x EBITDA with 11.3x interest coverage, a balance sheet setup that supports the 3.6% shareholder yield through dividends and repurchases.

Analysts price the stock at $142.77, implying 21.8% upside, but commodity price risk remains the primary thesis driver; crude volatility can compress FCF faster than the payout ratio suggests.

2. Newmont Corporation (NEM)

Dividend yield: 1.1% | Payout ratio: 15.7% | 52w drawdown: 27.9%

Newmont trades at a 27.9% drawdown with 7.0% FCF yield and a 15.7% payout ratio, the lowest cover ratio in the top five. ROIC is 29.9%, revenue grew 21.3%, and gross margin stands at 53.2%, all reflecting higher realized gold prices and operational leverage from the Newcrest acquisition.

Mark Rodgers, Brian Tabolt, and David Thornton each filed sales on July 29, part of a six-month insider pattern showing 100% sell-side activity and net share reduction of 18,394. The stock trades at 12.6x earnings with analysts pricing it at $142.82, implying 46.9% upside.

Net debt is negative at -0.20x EBITDA, but the setup depends on gold holding above $2,400; a metal price retreat would compress the FCF yield and test the dividend sustainability given the low payout cover.

3. Novartis AG (NVS)

Dividend yield: 3.1% | Payout ratio: 64.7% | 52w drawdown: 9.7%

Novartis sits at a 9.7% drawdown with 5.2% FCF yield and a 3.1% dividend yield backed by 64.7% payout ratio and five-year dividend growth averaging 7.2% annually. Revenue rose 9.6% with 75.8% gross margin, reflecting pricing power in the cardiovascular and ophthalmology franchises.

Analysts price the stock at $153.87, flat to the current $153.90, signaling limited upside beyond the dividend. Net debt sits at 1.75x EBITDA, higher than ConocoPhillips or EOG, and interest coverage of 15.3x is adequate but not exceptional for a pharma major.

4. EOG Resources, Inc. (EOG)

Dividend yield: 2.9% | Payout ratio: 43.6% | 52w drawdown: 5.9%

EOG trades at a 5.9% drawdown with 4.5% FCF yield and a 2.9% dividend yield, supported by 43.6% payout ratio and 28.1x interest coverage. ROIC is 15.2% with net debt at 0.35x EBITDA, one of the cleanest balance sheets among North American E&Ps.

Christopher Gaut, Charles Crisp, and Janet Clark each sold shares on August 4, part of a six-month pattern showing 100% sell-side activity and net share reduction of 14,343. The stock trades near 52-week highs despite revenue declining 3.4% year-over-year.

Analysts price the stock at $160.25, implying 12.2% upside, but the thesis depends on sustained $75+ WTI; below that level, the FCF yield compresses and the premium valuation relative to peers becomes harder to justify.

5. Biogen Inc. (BIIB)

Dividend yield: n/a | Payout ratio: 0.0% | 52w drawdown: 2.1%

Biogen trades at a 2.1% drawdown with 6.6% FCF yield and no dividend, freeing the entire cash flow for reinvestment or buybacks. Revenue grew 2.2% with 75.7% gross margin, and ROIC sits at 7.0%, reflecting the Alzheimer's portfolio transition and Skyclarys launch in Friedreich's ataxia.

Insiders filed 10 Form 4 transactions over six months with net share additions of 3, showing 100% buy-side activity. The stock trades at 21.7x earnings with analysts pricing it at $219.44, implying 8.8% upside.

Net debt stands at 0.64x EBITDA with 6.8x interest coverage, the weakest debt profile in the top five, and short interest is 3.2% of float; the setup depends on Leqembi revenue scaling faster than consensus expects.

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.

6. KLA Corporation (KLAC)

Dividend yield: 4.8% | Payout ratio: 29.6% | 52w drawdown: 90.7%

KLA trades at a 90.7% drawdown with 15.0% FCF yield, the highest on the screen, and a 4.8% dividend yield backed by 29.6% payout ratio. ROIC is 66.5%, revenue grew 23.9%, and gross margin is 60.9%, all reflecting the process control equipment oligopoly in leading-edge semiconductor manufacturing.

Bren Higgins sold shares on July 6, Richard Wallace on August 3, and Mary Beth Wilkinson on August 4, but the stock remains near $190 while analysts price it at $1,855.14, implying 872.6% upside if the pre-drawdown valuation is correct.

The 90.7% drawdown signals either a terminal thesis break or the deepest value trap on the screen; the earnings yield is 18.5%, but the setup depends on semiconductor capex returning to 2024 levels, which remains speculative.

7. The Cigna Group (CI)

Dividend yield: 2.3% | Payout ratio: 27.7% | 52w drawdown: 19.0%

Cigna trades at a 19.0% drawdown with 11.6% FCF yield and a 2.3% dividend yield backed by 27.7% payout ratio, leaving headroom for buybacks. Revenue grew 11.7% with ROIC at 11.2%, reflecting Evernorth's specialty pharmacy and biosimilar distribution scale.

James Lee filed two purchases on July 24 and August 3, adding shares while the stock traded in the $270–$280 range. Net debt sits at 1.72x EBITDA with 6.5x interest coverage, in line with managed care sector norms.

Jefferies downgraded the stock to Hold on mounting 2027 earnings headwinds, and analysts price it at $341.50, implying 24.5% upside; the setup depends on Evernorth's margin expansion offsetting pressure in the Cigna Healthcare segment.

8. Gilead Sciences, Inc. (GILD)

Dividend yield: 2.5% | Payout ratio: 47.9% | 52w drawdown: 16.7%

Gilead trades at a 16.7% drawdown with 5.8% FCF yield and a 2.5% dividend yield backed by 47.9% payout ratio. ROIC is 24.4%, revenue grew 2.4%, and gross margin is 78.8%, all reflecting the HIV franchise's pricing power and oncology portfolio expansion.

Andrew Dickinson and Johanna Mercier sold shares on July 16, and Daniel O'Day on August 4, part of a pattern of executive sales while the stock traded in the $125–$135 range. Net debt sits at 0.84x EBITDA with 10.6x interest coverage.

Analysts price the stock between $120 and $135, implying limited upside beyond the dividend; the setup depends on lenacapavir's HIV prevention approval and Trodelvy's label expansion, both of which remain binary catalysts.

What to Watch

• ConocoPhillips earnings (August 6): consensus expects $2.89 EPS and $19.8B revenue; upside would validate the 5.1% FCF yield and 21.8% analyst upside target.

• KLA's next filing or guidance update: the 90.7% drawdown requires either a catalyst to confirm the recovery thesis or a thesis break signal; watch for any semiconductor capex commentary from Taiwan Semiconductor or ASML.

• Cigna's 2027 outlook clarity: Jefferies flagged earnings headwinds; any management commentary on Evernorth's margin trajectory or Medicare Advantage pricing will move the stock.

• Gold price action: Newmont's 46.9% analyst upside depends on metal prices holding above $2,400; watch for Fed commentary that shifts real rate expectations.

Go Deeper

The dividend screener surfaces stocks with sustainable yields, strong FCF cover, and insider alignment.
Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Stock Pixie Pro

See the full dividend screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial →

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.